KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Go back to KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma| Merck & Co. (NYSE: MRK) | Delayed: 120.18 -0.58 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $120.76 | 52 Week High | $65.46 | |||
| Open | $121.50 | 52 Week Low | $47.97 | |||
| Day High | $121.90 | P/E | 81.76 | |||
| Day Low | $119.67 | EPS | $1.47 | |||
| Volume | 4,471,468 | |||||
